Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Vertex, Inc. (NASDAQ:VERX – Free Report) by 53.4% ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use beyond acute pain management.

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Vertex (VERX – Research Report) and AppLovin ...

Vertex maintains a dominant position in the cystic fibrosis market, with its CF franchise demonstrating robust growth and durability. Analysts project an 8% year-over-year growth at the midpoint ...

India's tech start-ups raised $2.5 billion in Q1 2025, with Auto Tech, Enterprise Applications, and Retail leading sectors.

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...